Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas

References

• Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403.
   PubMed Web of Science ®Google Scholar
• He J, Blair AB, Groot VP, et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018;268(1):1–8.
   PubMed Web of Science ®Google Scholar
• Tucker ON, Rela M. Controversies in the management of borderline resectable proximal pancreatic adenocarcinoma with vascular involvement. HPB Surg. 2008;2008:839503.
   PubMedGoogle Scholar
• Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, Phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(2):128–138.
   PubMed Web of Science ®Google Scholar
• Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J ClinOncol. 2021;29(22):3037–3043.
   Web of Science ®Google Scholar
• Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J ClinOncol. 2009;27(11):1806–1813.
   PubMed Web of Science ®Google Scholar
• Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–1853.
   PubMed Web of Science ®Google Scholar
• Kang CM, Hwang HK, Choi SH, Lee WJ. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. SurgOncol. 2013;22(2):123–131.
   Google Scholar
• Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27(13):2269–2277.
   PubMed Web of Science ®Google Scholar
• Buss EJ, Kachnic LA, Horowitz DP. Radiotherapy for locally advanced pancreatic ductal adenocarcinoma. Semin Oncol. 2021;48(1):106–110.
   PubMed Web of Science ®Google Scholar
• Li X, Lin H, Ouyang R, Yang Y, Peng J. Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: a meta-analysis. Biosci Rep. 2021;41(8):BSR20204401.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 2010;24:349–358.
   PubMed Web of Science ®Google Scholar
• Steele CW, Jamieson NB, Evans TR, et al. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer. 2013;108(5):997–1003.
   PubMed Web of Science ®Google Scholar
• Martin HL, Ohara K, Kiberu A, et al. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J. 2014;44(7):676–682.
   PubMed Web of Science ®Google Scholar
• Birtolo C, Go VL, Ptasznik A, et al. Phosphatidylinositol 3-Kinase: a link between inflammation and pancreatic cancer. Pancreas. 2016;45(1):21–31.
   PubMed Web of Science ®Google Scholar
• Shui Y, Li M, Su J, Chen M, Gu X, Guo W. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2365 patients. Aging. 2021;13(16):20585–20597.
   PubMedGoogle Scholar
• Garcea G, Ladwa N, Neal CP, et al. Preoperative neutrophil to lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011;35:868–872.
   PubMed Web of Science ®Google Scholar
• Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–421.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Taniguchi K, Asakuma M, et al. Lymphocyte-to-monocyte ratio and prognostic nutritional index predict poor prognosis in patients on chemotherapy for unresectable pancreatic cancer. Anticancer Res. 2019;39(4):2169–2176.
   PubMed Web of Science ®Google Scholar
• Yamada S, Fujii T, Yabusaki N, et al. Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter. Medicine. 2016;95(18):e3582.
   PubMed Web of Science ®Google Scholar
• Geng Y, Qi Q, Sun M, et al. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol. 2015;41(11):1508–1514.
   PubMed Web of Science ®Google Scholar
• Jomrich G, Gruber ES, Winkler D, et al. systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg. 2020;24(3):610–618.
   PubMed Web of Science ®Google Scholar
• Topkan E, Mertsoylu H, Kucuk A, et al. Low systemic inflammation response index predicts good prognosis in locally advanced pancreatic carcinoma patients treated with concurrent chemoradiotherapy. Gastroenterol Res Pract. 2020;2020:5701949.
   PubMed Web of Science ®Google Scholar
• Topkan E, Mertsoylu H, Ozdemir Y, et al. Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy. Cancer Manag Res. 2019;11:8807–8815.
   PubMed Web of Science ®Google Scholar
• Topkan E, Selek U, Pehlivan B, et al. The prognostic significance of novel pancreas cancer prognostic index in unresectable locally advanced pancreas cancers treated with definitive concurrent chemoradiotherapy. J Inflamm Res. 2021;14:4433–4444.
   PubMed Web of Science ®Google Scholar
• Fucà G, Guarini V, Antoniotti C, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403–409.
   PubMed Web of Science ®Google Scholar
• Corti F, Lonardi S, Intini R, et al. The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021;150:155–167.
   PubMed Web of Science ®Google Scholar
• Sato S, Shimizu T, Ishizuka M, et al. The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery. Surg Today. 2022;10:1–10.
   Google Scholar
• Ligorio F, Fucà G, Zattarin E, et al. The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers. 2021;13(8):1964.
   PubMed Web of Science ®Google Scholar
• Sahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep. 2021;11(1):14662.
   PubMed Web of Science ®Google Scholar
• Demir H, Demirci A, Eren SK, Beypinar I, Davarcı SE, Baykara M. A new prognostic index in young breast cancer patients. J Coll Physicians Surg Pak. 2022;32(1):86–91.
   PubMed Web of Science ®Google Scholar
• Zeng R, Liu F, Fang C, et al. PIV and PILE Score at baseline predict clinical outcome of anti-PD-1/PD-L1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients. Front Immunol. 2021;12:724443.
   PubMed Web of Science ®Google Scholar
• Yoshifumi B, Shigeki N, Tasuku T, et al. Pan-immune-inflammation value and prognosis in patients with esophageal cancer. Ann Surg. 2022;3(1):e113.
   Google Scholar
• Chen X, Hong X, Chen G, et al. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor. Transl Oncol. 2022;17:101338.
   PubMed Web of Science ®Google Scholar
• Gambichler T, Said S, Abu Rached N, et al. Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma. J Cancer Res Clin Oncol. 2022. doi:10.1007/s00432-022-03929-y
   Web of Science ®Google Scholar
• Fucà G, Beninato T, Bini M, et al. The Pan-Immune-Inflammation Value in patients with metastatic melanoma receiving first-line therapy. Target Oncol. 2021;16(4):529–536.
   PubMed Web of Science ®Google Scholar
• Pérez-Martelo M, González-García A, Vidal-ínsua Y, et al. Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy. Sci Rep. 2022;12(1):6893.
   PubMed Web of Science ®Google Scholar
• Guven DC, Yildirim HC, Bilgin E, et al. PILE: a candidate prognostic score in cancer patients treated with immunotherapy. Clin Transl Oncol. 2021;23(8):1630–1636.
   PubMed Web of Science ®Google Scholar
• Guven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, Aksoy S. The association between the pan-immune-inflammation value and cancer prognosis: a systematic review and meta-analysis. Cancers. 2022;14(11):2675.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–277.
   PubMed Web of Science ®Google Scholar
• Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. 2019;20(3):676.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444.
   PubMed Web of Science ®Google Scholar
• Dell’Aquila E, Fulgenzi CAM, Minelli A, et al. Prognostic and predictive factors in pancreatic cancer. Oncotarget. 2020;11(10):924–941.
   PubMedGoogle Scholar
• Berger AC, Winter K, Hoffman JP, et al. Five-year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012;84(3):e291–e297.
   PubMed Web of Science ®Google Scholar
• Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25(7):717–729.
   PubMed Web of Science ®Google Scholar
• Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol. 2013;4:56.
   PubMed Web of Science ®Google Scholar